Enrolling by invitationPhase 2NCT05957913
Effects of Antiviral Therapies on Epstein-Barr Virus Replication
Studying Multiple sclerosis variant
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Michael Levy, MD, PhDMassachusetts General Hospital
- Intervention
- Truvada (tenofovir/emtricitabine)(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (1)
- Massachusetts General Hospital, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05957913 on ClinicalTrials.govOther trials for Multiple sclerosis variant
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06992115A Study of the MIND Diet for Persons With Multiple SclerosisIcahn School of Medicine at Mount Sinai
- RECRUITINGNANCT07175792Accuracy of Motor Performance Perception in Multiple SclerosisHasselt University
- RECRUITINGNANCT06668649Polish Version Fatigue Severity ScaleJakub Antczak
- RECRUITINGNCT06516458Development of Camera Based Gait Quality Measure for Persons With Multiple SclerosisShirley Ryan AbilityLab
- RECRUITINGNANCT06312046Motor-cognitive Performance in People With Multiple SclerosisKarolinska Institutet
- ENROLLING BY INVITATIONNCT07025122Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the DiseaseUniversity Hospital, Martin
- ACTIVE NOT RECRUITINGNANCT05391906Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in Multiple SclerosisChinese University of Hong Kong